Serum testosterone changes in patients treated with radiation therapy alone for prostate cancer on NRG oncology RTOG 9408

by R. Charles Nichols, MD, Chen Hu, PhD, Jean-Paul Bahary, MD, Kenneth L. Zeitzer, MD, Luis Souhami, MD, Mark H. Leibenhaut, MD, Marvin Rotman, MD, Elizabeth M. Gore, MD, Alexander G. Balogh, MD, David McGowan, MD, Jeff Michalski, MD, Adam Raben, MD, Shari Rudoler, MD, Christopher U. Jones, MD, Howard Sandler, MD
Published 2017-10-01

Risk factors for late bowel and bladder toxicities in NRG Oncology prostate cancer trials of high-risk patients: A meta-analysis of physician-rated toxicities

by Canhua Xiao, PhD, Jennifer Moughan, MS, Benjamin Movsas, MD, Andre A. Konski, MD, Gerald E. Hanks, MD, James D. Cox, MD, Mack Roach, III, MD, Kenneth L. Zeitzer, MD, Colleen A. Lawton, MD, Christopher A. Peters, MD, Seth A. Rosenthal, MD, I.-Chow Joe Hsu, MD, Eric M. Horwitz, MD, Mark V. Mishra, MD, Jeff M. Michalski, MD, Matthew B. Parliament, MD, David P. D'Souza, MD, Stephanie L. Pugh, PhD, Deborah W. Bruner, PhD
Published 2018-07-01